Effects of glucosyl hesperidin on serum lipids in hyperlipidemic subjects: Preferential reduction in elevated serum triglyceride level

Journal of Nutritional Science and Vitaminology

Volumn 50, Issue 3, 2004, Pages 211-218

  Miwa, Yoshikatsu ^a   Yamada, Mika ^a   Sunayama, Takahiro ^b   Mitsuzumi, Hitoshi ^a   Tsuzaki, Yukari ^a   Chaen, Hiroto ^a   Mishima, Yasuo ^b   Kibata, Masayoshi ^a,c  

^a HAYASHIBARA BIOCHEMICAL LABORATORIES INC   (Japan)

^b Dai ichi Central Bldg Clinic ^*  (Japan)

^c Division of Internal Medicine   (Japan)

Author keywords

Apolipoprotein; Glucosyl hesperidin; Small dense LDL; Triglyceride

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN C2; APOLIPOPROTEIN E; GLUCOSYLHESPERIDIN; HESPERIDIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CATABOLISM; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; LIPID METABOLISM; MALE; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL; TABLET; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALIA;

EID: 3843091433     PISSN: 03014800     EISSN: 18817742     Source Type: Journal    
DOI: 10.3177/jnsv.50.211     Document Type: Article

References (41)

1. Garg A, Garg S, Zaneveld LJD, Singla AK. 2001. Chemistry and pharmacology of the citrus bioflavonoid hesperidin. Phytother Res 15: 655-669.
2. Rathi AB, Nath N, Chari SN. 1983. Action of vitamin P like compounds on lysosomal status in hypercholesterolemic rats. Acta Vitaminol Enzymol 5: 255-261.
3. Monforte MT, Trovato A, Kirjavainen S, Forestieri AM, Galati EM, Lo Curto RB. 1995. Biological effects of hesperidin, a citrus flavonoid. (note II): hypolipidemic activity on experimental hypercholesterolemia in rat. IL Farmaco 50: 595-599.
4. Bok SH, Lee SH, Park YB, Bae KH, Son KH, Jeong TS, Choi MS. 1999. Plasma and hepatic cholesterol and hepatic activities of 3-hydroxy-3-methyl-glutaryl- CoA reductase and acyl CoA: cholesterol transferase are lower in rats fed citrus peel extract or a mixture of citrus bioflavonoids. J Nutr 129: 1182-1185.
5. Park YB, Do KM, Bok SH, Lee MK, Jeong TS, Choi MS. 2001. Interactive effect of hesperidin and vitamin E supplements on cholesterol metabolism in high cholesterol-fed rats. Int J Vitam Nutr Res 71: 36-44.
6. Kawaguchi K, Mizuno T, Aida K, Uchino K. 1997. Hesperidin as an inhibitor of lipases from porcine pancreas and Pseudomonas. Biosci Biotechnol Biochem 61: 102-104.
7. Demchuk AM, Hess DC, Brass LM, Yatsu FM. 1999. Is cholesterol a risk factor for stroke? Yes. Arch Neurol 56: 1518-1520.
8. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ. 1995. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333: 1301-1307.
9. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun CC, Davis BR, Braunwald E. 1996. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335: 1001-1009.
10. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Mänttäri M, Heinonen OP, Frick MH. 1992. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 85: 37-45.
11. Grundy SM, Vega GL. 1992. Two different views of the relationship of hypertriglyceridemia to coronary heart disease. Implications for treatment. Arch Intern Med 152: 28-34.
12. Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, Hemphill LC, Kramsch DM, Blankenhorn DH. 1994. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 90: 42-49.
13. Feingold KR, Grunfeld C, Pang M, Doerrler W, Krauss RM. 1992. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb 12: 1496-1502.
14. Kazumi T, Kawaguchi A, Hozumi T, Nagao M, Iwahashi M, Hayakawa M, Ishihara K, Yoshino G. 1999. Low density lipoprotein particle diameter in young, non-obese, normolipidemic Japanese men. Atherosclerosis 142: 113-119.
15. McNamara JR, Jenner JL, Li Z, Wilson PWF, Schaefer EJ. 1992. Change in LDL particle size is associated with change in plasma triglyceride concentration. Arterioscler Thromb 12: 1284-1290.
16. Austin MA, Mykkänen L, Kuusisto J, Edwards KL, Nelson C, Haffner SM, Pyörälä K, Laakso M. 1995. Prospective study of small LDLs as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women. Circulation 92: 1770-1778.
17. Hijiya H, Miyake T. 1991. Alpha-glycosyl hesperidin, and its preparation and uses. European Patent Publication No. 0402049.
18. Ohtsuki K, Abe A, Mitsuzumi H, Kondo M, Uemura K, Iwasaki Y, Kondo Y. 2002. Effects of long-term administration of hesperidin and glucosyl hesperidin to spontaneously hypertensive rats. J Nutr Sci Vitaminol 48: 420-422.
19. Yamada M, Mitsuzumi H, Tsuzaki Y, Miwa Y, Chaen H, Yamamoto I. 2003. Antioxidant activity of glucosylated vitamin P and its suppressive effect on oxidative stress in hyperlipidemic mice. J Jpn Soc Nutr Food Sci 56: 355-363.
20. McNamara JR, Small DM, Li Z, Schaefer EJ. 1996. Differences in LDL subspecies involve alterations in lipid composition and conformational changes in apolipoprotein B. J Lipid Res 37: 1924-1935.
21. Bruckert E, De Gennes JL, Malbecq W, Baigts F. 1995. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia. Clin Cardiol 18: 621-629.
22. Ikeda Y, Takagi A. 2001. Involvement of environmental factors on development of hyperlipidemia. Nippon Rinsho 59 (suppl 2): 670-676.
23. Shiomi M, Ito T. 2001. Animal models for spontaneous hyperlipidemia. Nippon Rinsho 59 (suppl 2): 617-620.
24. Tsujita Y, Kuroda M, Shimada Y, Tanzawa K, Arai M. Kaneko I, Tanaka M, Masuda H, Tarumi C, Watanabe Y, Fujii S. 1986. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. Biochim Biophys Acta 877: 50-60.
25. Endo A, Tsujita Y, Kuroda M, Tanzawa K. 1979. Effects of ML-236B on cholesterol metabolism in mice and rats: lack of hypocholesterolemic activity in normal animals. Biochim Biophys Acta 575: 266-276.
26. Endo A. 1988. Chemistry, biochemistry, and pharmacology of HMG-CoA reductase inhibitors. Klin Wochenschr 66: 421-427.
27. Fujioka T, Nara F, Tsujita Y, Fukushige J, Fukami M, Kuroda M. 1995. The mechanism of lack of hypocholesterolemic effects of pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rats. Biochim Biophys Acta 1254: 7-12.
28. Andersson Y, Majd Z, Lefebvre AM, Martin G, Sechkin AV, Kosykh V, Fruchart JC, Najib J, Staels B. 1999. Developmental and pharmacological regulation of apolipoprotein C-II gene expression. Comparison with apo C-I and apo C-III gene regulation. Arterioscler Thromb Vasc Biol 19: 115-121.
29. Weisgraber KH. 1994. Apolipoprotein E: structure-function relationships. Adv Protein Chem 45: 249-302.
30. Schoonjans K, Staels B, Auwerx J. 1996. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 37: 907-925.
31. Staels B, Vu-Dac N, Kosykh VA, Saladin R, Fruchart JC, Dallongeville J, Auwerx J. 1995. Fibrates down-regulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 95: 705-712.
32. Haubenwallner S, Essenburg AD, Barnett BC, Pape ME, DeMattos RB, Krause BR, Minton LL, Auerbach BJ, Newton RS, Leff T, Bisgaier CL. 1995. Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action. J Lipid Res 36: 2541-2551.
33. Nozue T, Inazu A, Mabuchi H. 2001. High density lipoprotein. Nippon Rinsho 59 (suppl 2): 75-79.
34. Okada M. 2001. Functions of cholesteryl ester transfer protein (CETP). Nippon Rinsho 59 (suppl 2): 236-239.
35. Borradaile NM, Carroll KK, Kurowska EM. 1999. Regulation of HepG2 cell apolipoprotein B metabolism by the citrus flavanones hesperetin and naringenin. Lipids 34: 591-598.
36. Wilcox LJ, Borradaile NM, de Dreu LE, Huff MW. 2001. Secretion of hepatocyte apoB is inhibited by the flavonoids, naringenin and hesperetin, via reduced activity and expression of ACAT2 and MTP. J Lipid Res 42: 725-734.
37. Ameer B, Weintraub RA, Johnson JV, Yost RA, Rouseff RL. 1996. Flavanone absorption after naringin, hesperidin, and citrus administration. Clin Pharmacol Ther 60: 34-40.
38. Manach C, Morand C, Gil-Izquierdo A, Bouteloup-Demange C, Rémésy C. 2003. Bioavailability in humans of the flavanones hesperidin and narirutin after the ingestion of two doses of orange juice. Eur J Clin Nutr 57: 235-242.
39. Tan CE, Forster L, Caslake MJ, Bedford D, Watson TDG, McConnell M, Packard CJ, Shepherd J. 1995. Relations between plasma lipids and postheparin plasma lipases and VLDL and LDL subfraction patterns in normolipemic men and women. Arterioscler Thromb Vasc Biol 15: 1839-1848.
40. Sone H, Takahashi A, Shimano H, Ishibashi S, Yoshino G, Morisaki N, Saito Y, Kawazu S, Teramoto T, Fujita T, Shiba T, Iwamoto Y, Kuzuya N, Akanuma Y, Yamada N. 2002. HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes. Life Sci 71: 2403-2412.
41. Guerin M, Egger P, Soudant C, Le Goff W, van Tol A, Dupuis R, Chapman MI. 2002. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apo B-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Atherosclerosis 163: 287-296.